We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$650M
AUM Growth
+$95.3M
Cap. Flow
+$75.6M
Cap. Flow %
11.63%
Top 10 Hldgs %
57.73%
Holding
90
New
18
Increased
17
Reduced
23
Closed
25

Top Buys

Rank Stock Value
1
NPCE icon
Neuropace
NPCE
+$32.1M
2
FOCL
EDAP TMS S.A.
FOCL
+$16.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$14.6M
4
NVCR icon
NovoCure
NVCR
+$14.3M
5
NEO icon
NeoGenomics
NEO
+$13.6M

Top Sells

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$17.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$8.74M
3
KRYS icon
Krystal Biotech
KRYS
+$6.93M
4
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$5.31M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$4.68M

Sector Composition

Rank Sector Weight
1 Healthcare 90.8%
2 Consumer Staples 2.41%
3 Financials 0.49%
4 Real Estate 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
76
Palvella Therapeutics
PVLA
$2.04B
– –
-6,250
Closed -$1.28M
RVNC
77
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-31,136
Closed -$870K
MORF
78
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-21,500
Closed -$1.36M
ALPN
79
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-313,064
Closed -$3.32M
KNTE
80
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-109,000
Closed -$3.4M
MRTX
81
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-3,466
Closed -$594K
ONCR
82
DELISTED
Oncorus, Inc.
ONCR
– –
-66,722
Closed -$929K
OSH
83
DELISTED
Oak Street Health, Inc.
OSH
– –
-27,612
Closed -$1.5M
TPTX
84
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-5,577
Closed -$528K
FLXN
85
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-522,500
Closed -$4.68M
TRIL
86
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-103,819
Closed -$1.11M
HIMS.WS
87
DELISTED
Hims & Hers Health, Inc. Warrants, each whole warrant exercisable for one Class A Common Stock at an
HIMS.WS
– –
-91,793
Closed -$404K
ALXN
88
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-25,318
Closed -$3.87M
1 2 3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Soleus Capital Management held 90 positions worth $650M, up 17% from $555M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Soleus Capital Management deployed $75.6M of net new capital in Q2 2021, opening 18 new positions and adding to 17 existing holdings. Its largest new stake was Neuropace: 1,384,387 shares worth $32.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was BioAtla, an estimated $17.4M trimmed.

  • Soleus Capital Management's largest Q2 2021 buy was Neuropace: 1,384,387 shares worth $32.9M.
  • Soleus Capital Management added most to EDAP TMS S.A. in Q2 2021, an estimated $16.9M increase.
  • Soleus Capital Management's biggest Q2 2021 reduction was BioAtla, cutting an estimated $17.4M.
  • Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q2 2021, selling an estimated $4.68M.
  • Soleus Capital Management's ten largest holdings make up 58% of its $650M portfolio in Q2 2021.
  • Soleus Capital Management opened 18 new positions and closed 25 in Q2 2021.
  • Soleus Capital Management's portfolio value rose 17% quarter-over-quarter to $650M.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.